Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Single-center Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

NCT04688021 is registered in ClinicalTrials.gov with Yi Luo as lead sponsor.

NCT NCT04688021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04688021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Single-center Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
Lead sponsor
Yi Luo
Phase
Phase 2
Overall status
Unknown status
Start date
December 3, 2020
Completion date
December 31, 2024
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host-disease, leukemia